PUBLISHER: IMARC | PRODUCT CODE: 1451731
PUBLISHER: IMARC | PRODUCT CODE: 1451731
Epilepsy Drugs Market by Generation Type, Anti-Epileptics Drugs Type, Distribution Channel, and Region 2024-2032
The global epilepsy drugs market size reached US$ 2.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.4 Billion by 2032, exhibiting a growth rate (CAGR) of 7.16% during 2024-2032. The rising prevalence of epilepsy, increasing incidences of brain cancer in the geriatric population, and extensive research and development (R&D) activities represent some of the key factors driving the market.
Epilepsy drugs refer to medications used for treating epilepsy, a central nervous system (CNS) disorder that causes unpredictive, unprovoked, and recurrent episodes of seizures. Epilepsy affects various mental and physical functions causing sudden behavioral changes, sensations, loss of awareness, and severe emotional distress. Its medication includes first-, second-, and third-generation anti-epileptic drugs (AEDs), such as tablets, capsules, liquids, and syrups that are administered through oral, intravenous (IV), and intramuscular routes. Epilepsy drugs are widely used to treat various seizures, including partial onset, hard-to-treat, mixed, tonic-clonic, and acute repetitive seizures. Epilepsy drugs are safe, offer better tolerability, prevent life-threatening adverse effects, and minimize the negative impact on the cognitive functions.
At present, the rising prevalence of epilepsy due to increasing incidences of neurological disorders, birth-related injuries, infections, substance abuse, and road injuries is one of the primary factors driving the market growth. Epilepsy drugs are widely used to eliminate seizures, reduce their frequency, and evade the adverse effects associated with long-term treatments, thus helping patients in restoring their usual psychosocial and vocational activities and maintaining a normal lifestyle. In addition to this, the rising geriatric population that is prone to developing critical ailments, such as brain cancer, that can cause seizures, is acting as another major growth-inducing factor. Furthermore, extensive research and development (R&D) activities toward developing new and advanced drugs that are affordable and provide improved tolerability and efficacy with fewer side effects are currently positively influencing the market growth. Apart from this, the recent development of extended-release (ER) drug formulations that allow longer dosing intervals while minimizing the fluctuations in serum drug levels, thus improving efficacy and adherence as compared to immediate-release (IR) drugs, is facilitating the market growth. Moreover, the implementation of various government initiatives to educate the masses about the disorder, promote research, and provide active support by expediting better treatment options are propelling the market growth. Other factors, including the rising approval of novel drugs, rapid improvements in healthcare infrastructural facilities, increasing public awareness regarding the available treatments of neurological disorders, and the decreasing stigma associated with epilepsy, are anticipated to drive the market toward growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global epilepsy drugs market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on generation type, anti-epileptics drugs type and distribution channel.
Generation Type Insights
First Generation Drugs
Phenytoin
Carbamazepine
Oxcarbazepine
Valproate
Ethosuximide
Primidone
Phenobarbital
Second Generation Drugs
Levetiracetam
Lamotrigine
Topiramate
Pregabalin
Rufinamide
Zonisamide
Third Generation Drugs
Lacosamide
Perampanel
Eslicarbazepine Acetate
Ezogabine/Retigabine
The report has also provided a detailed breakup and analysis of the epilepsy drugs market based on the generation type. This includes first generation drugs (phenytoin, carbamazepine, oxcarbazepine, valproate, ethosuximide, primidone, and phenobarbital), second generation drugs (levetiracetam, lamotrigine, topiramate, pregabalin, rufinamide, and zonisamide), and third generation drugs (lacosamide, perampanel, eslicarbazepine acetate, and ezogabine/retigabine). According to the report, second generation drugs represented the largest segment.
Anti-Epileptics Drugs Type Insights
Narrow-Spectrum AEDs
Broad-Spectrum AEDs
A detailed breakup and analysis of the epilepsy drugs market based on the anti-epileptics drugs type has also been provided in the report. This includes narrow and broad-spectrum AEDs. According to the report, broad-spectrum AEDs accounted for the largest market share.
Distribution Channel Insights
Hospital Pharmacy
Pharmacy Stores
Others
A detailed breakup and analysis of the epilepsy drugs market based on the distribution channel has been provided in the report. This includes hospital pharmacy, pharmacy stores, and others. According to the report, hospital pharmacy accounted for the largest market share.
Regional Insights:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for epilepsy drugs. Some of the factors driving the North America epilepsy drugs market growth include increasing burden of epilepsy, rising awareness campaigns, launching of new products, etc.
Competitive Landscape
The report has also provided a comprehensive analysis of the competitive landscape in the global epilepsy drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Alkem Laboratories Limited, Bausch Health Companies Inc., Eisai Co. Ltd., GSK plc, H. Lundbeck A/S, Jazz Pharmaceuticals plc, Novartis AG, Pfizer Inc., Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd.), UCB S.A., etc. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in This Report:
- How has the global epilepsy drugs market performed so far and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global epilepsy drugs market?
- What are the key regional markets?
- Which countries represent the most attractive epilepsy drugs markets?
- What is the breakup of the market based on the generation type?
- What is the breakup of the market based on the anti-epileptics drugs type?
- What is the breakup of the market based on the distribution channel?
- What is the competitive structure of the global epilepsy drugs market?
- Who are the key players/companies in the global epilepsy drugs market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Epilepsy Drugs Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Generation Type
- 6.1 First Generation Drugs
- 6.1.1 Market Trends
- 6.1.2 Key Segments
- 6.1.2.1 Phenytoin
- 6.1.2.2 Carbamazepine
- 6.1.2.3 Oxcarbazepine
- 6.1.2.4 Valproate
- 6.1.2.5 Ethosuximide
- 6.1.2.6 Primidone
- 6.1.2.7 Phenobarbital
- 6.1.3 Market Forecast
- 6.2 Second Generation Drugs
- 6.2.1 Market Trends
- 6.2.2 Key Segments
- 6.2.2.1 Levetiracetam
- 6.2.2.2 Lamotrigine
- 6.2.2.3 Topiramate
- 6.2.2.4 Pregabalin
- 6.2.2.5 Rufinamide
- 6.2.2.6 Zonisamide
- 6.2.3 Market Forecast
- 6.3 Third Generation Drugs
- 6.3.1 Market Trends
- 6.3.2 Key Segments
- 6.3.2.1 Lacosamide
- 6.3.2.2 Perampanel
- 6.3.2.3 Eslicarbazepine Acetate
- 6.3.2.4 Ezogabine/Retigabine
- 6.3.3 Market Forecast
7 Market Breakup by Anti-Epileptics Drugs Type
- 7.1 Narrow-Spectrum AEDs
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Broad-Spectrum AEDs
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
8 Market Breakup by Distribution Channel
- 8.1 Hospital Pharmacy
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Pharmacy Stores
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
- 10.1 Overview
- 10.2 Drivers
- 10.3 Restraints
- 10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Abbott Laboratories
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Alkem Laboratories Limited
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Bausch Health Companies Inc.
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Eisai Co. Ltd.
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 GSK plc
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 H. Lundbeck A/S
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.7 Jazz Pharmaceuticals plc
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.7.4 SWOT Analysis
- 14.3.8 Novartis AG
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Pfizer Inc.
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd.)
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 SWOT Analysis
- 14.3.11 UCB S.A.
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.11.3 Financials
- 14.3.11.4 SWOT Analysis
- 14.3.1 Abbott Laboratories
Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report
List of Figures
- Figure 1: Global: Epilepsy Drugs Market: Major Drivers and Challenges
- Figure 2: Global: Epilepsy Drugs Market: Sales Value (in Billion US$), 2018-2023
- Figure 3: Global: Epilepsy Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
- Figure 4: Global: Epilepsy Drugs Market: Breakup by Generation Type (in %), 2023
- Figure 5: Global: Epilepsy Drugs Market: Breakup by Anti-Epileptics Drugs Type (in %), 2023
- Figure 6: Global: Epilepsy Drugs Market: Breakup by Distribution Channel (in %), 2023
- Figure 7: Global: Epilepsy Drugs Market: Breakup by Region (in %), 2023
- Figure 8: Global: Epilepsy Drugs (First Generation Drugs) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 9: Global: Epilepsy Drugs (First Generation Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 10: Global: Epilepsy Drugs (Second Generation Drugs) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 11: Global: Epilepsy Drugs (Second Generation Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 12: Global: Epilepsy Drugs (Third Generation Drugs) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 13: Global: Epilepsy Drugs (Third Generation Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 14: Global: Epilepsy Drugs (Narrow-Spectrum AEDs) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 15: Global: Epilepsy Drugs (Narrow-Spectrum AEDs) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 16: Global: Epilepsy Drugs (Broad-Spectrum AEDs) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 17: Global: Epilepsy Drugs (Broad-Spectrum AEDs) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 18: Global: Epilepsy Drugs (Hospital Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 19: Global: Epilepsy Drugs (Hospital Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 20: Global: Epilepsy Drugs (Pharmacy Stores) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 21: Global: Epilepsy Drugs (Pharmacy Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 22: Global: Epilepsy Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 23: Global: Epilepsy Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 24: North America: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 25: North America: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 26: United States: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 27: United States: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 28: Canada: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 29: Canada: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 30: Asia-Pacific: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 31: Asia-Pacific: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 32: China: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 33: China: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 34: Japan: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 35: Japan: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 36: India: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 37: India: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 38: South Korea: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 39: South Korea: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 40: Australia: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 41: Australia: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 42: Indonesia: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 43: Indonesia: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 44: Others: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 45: Others: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 46: Europe: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 47: Europe: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 48: Germany: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 49: Germany: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 50: France: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 51: France: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 52: United Kingdom: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 53: United Kingdom: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 54: Italy: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 55: Italy: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 56: Spain: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 57: Spain: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 58: Russia: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 59: Russia: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 60: Others: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 61: Others: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 62: Latin America: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 63: Latin America: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 64: Brazil: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 65: Brazil: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 66: Mexico: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 67: Mexico: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 68: Others: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 69: Others: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 70: Middle East and Africa: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 71: Middle East and Africa: Epilepsy Drugs Market: Breakup by Country (in %), 2023
- Figure 72: Middle East and Africa: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 73: Global: Epilepsy Drugs Industry: Drivers, Restraints, and Opportunities
- Figure 74: Global: Epilepsy Drugs Industry: Value Chain Analysis
- Figure 75: Global: Epilepsy Drugs Industry: Porter's Five Forces Analysis
List of Tables
- Table 1: Global: Epilepsy Drugs Market: Key Industry Highlights, 2023 & 2032
- Table 2: Global: Epilepsy Drugs Market Forecast: Breakup by Generation Type (in Million US$), 2024-2032
- Table 3: Global: Epilepsy Drugs Market Forecast: Breakup by Anti-Epileptics Drugs Type (in Million US$), 2024-2032
- Table 4: Global: Epilepsy Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
- Table 5: Global: Epilepsy Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
- Table 6: Global: Epilepsy Drugs Market: Competitive Structure
- Table 7: Global: Epilepsy Drugs Market: Key Players
